NextCure
Filed with the SEC on · accession 0001104659-26-123493
NXTC filed a S-4 (s-4) with the SEC on Nov 6, 2026. A report the company filed with the SEC (the US market regulator). The stock moved +4.1% by the first close after the filing.
NextCure filed an amended S-4 registration statement relating to its proposed merger with Avere Therapeutics, in which Avere will become a wholly owned subsidiary of NextCure and NextCure will re-domicile to Texas and rename itself Avere Therapeutics, Inc.
Close before
$5.12
Nov 5, 2026
First close after
+4.10%
$5.33
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for NXTC, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for NXTC?
Click hereNXTC filed a S-4 (Acquisition). NextCure filed an amended S-4 registration statement relating to its proposed merger with Avere Therapeutics, in which Avere will become a wholly owned subsidiary of NextCure and NextCure will re-domicile to Texas and rename itself Avere Therapeutics, Inc.
A contract important enough that investors need to know about it — a big customer contract, a loan, a merger agreement or a partnership.
A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A S-4 (s-4): A report the company filed with the SEC (the US market regulator).
NXTC closed at $5.12 before the filing and $5.33 on Nov 6, 2026 (+4.10%).
Get alerts when NXTC files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days